CDKN2B-AS1 and non-small cell lung carcinoma: Therefore, our results support the idea that ANRIL and/or UFC1 is an attractive target of drug development in tumor growth and the aggressive proliferation of NSCLC, and that a reasonable outcome can be achieved through the miRNA-34a/Myc pathway.